Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
November 6, 2025
Earnings Call Speaker Segments
Vivian Wu
executiveThanks, Crystal, and good afternoon to all of you. We appreciate you being with us today. Speaking on this call will be Howard Robin, our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and Sandra Gardiner, our Chief Financial Officer. Our Chief Medical Officer, Dr. Mary Tagliaferri, will also be around for the Q&A portion. During this call, we anticipate making forward-looking statements about the business, among them statements about rezpegaldesleukin's therapeutic potential and future development plans, the timing of and plans for upcoming clinical data presentations, and other statements concerning the future of our business. Since forward-looking statements concern the future, they carry uncertainties and risks that are hard to predict, and many of them lie beyond our control. Our actual results could differ materially from what these statements suggest. Key risks and uncertainties appear in our most recent Form 10-Q, which is available at sec.gov; we assume no obligation to update any forward-looking statements, whether because of new information, future developments or otherwise. A webcast of today's call will be accessible on the IR page of Nektar's website at nektar.com. Having said that, I'd like to turn the call over to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveThanks, Vivian, and hello everybody this afternoon. Prior to sharing my comments about the quarter, I want to spend a moment welcoming Dr. Mary Tagliaferri back to our organization. She recently returned to the role of Chief Medical Officer, having needed to take time away for personal matters earlier in the year. Mary played a key part in shaping and carrying out the Phase II program in atopic dermatitis that succeeded, and it's a real stroke of luck for us that she's with us again as we get ready to launch the Phase III program next year. I also want to express appreciation to Brian Kotzin for his assistance filling in as Interim CMO over that stretch. Brian has been with us for close to 10 years, and we feel fortunate that he'll stay on in a medical consulting capacity; throughout this quarter and the year so far, our attention has stayed sharply fixed on advancing regulatory T cell science throughout our pipeline and getting set to move our lead program, rezpegaldesleukin, or REZPEG, into Phase III development. Each of our pipeline programs aims to stimulate Tregs through distinct mechanisms in order to bring back the right equilibrium between T effector cells and T regulatory cells, producing homeostasis within the immune system. The atopic dermatitis results announced in June and shared at EADV 2025 for REZPEG amounted to a strong translation of the scientific findings that built our understanding of how essential Tregs are, becoming the first proof of their unambiguous clinical efficacy in autoimmune disease. The Nobel Prize in Physiology or Medicine was given out not long ago for those discoveries, which cemented FOXP3-positive Tregs as central enforcers of immune tolerance. We feel deeply humbled that the Nobel Committee cited the publication of the Phase Ib data for REZPEG in atopic dermatitis and psoriasis among the supporting background documents for that award. Having REZPEG acknowledged was a genuine honor and reflects the path our Nektar scientists and clinicians have walked across the years to convert significant scientific breakthroughs into genuine potential therapies for patients. Our strategy with REZPEG and Treg stimulation stands apart strongly within the field. We think this explains why we've managed to produce, uniquely, meaningful and robust clinical data that plainly justify further development of this novel modality. REZPEG was engineered to imitate closely how Tregs inside our own immune system function to settle inflammation. Its construct comes nearest to replicating natural human biology, doing so via IL-2 agonism with native sequence IL-2 receptor interactions plus a validated chemistry method, PEGylation, that has resulted in more than 2 dozen approved biologics. At the 2025 EADV Congress in September, we shared compelling findings from the 16-week induction period of the 400-patient RESOLVE-AD study of REZPEG in moderate to severe atopic dermatitis. Those data highlighted the clinical differentiation achievable through this novel MOA, and JZ will discuss that afterward on the call. Also, this coming weekend, during the 2025 American College of Allergy, Asthma and Immunology Annual Scientific Meeting, we're going to share findings from a preplanned analysis involving atopic dermatitis patients in the RESOLVE-AD study who additionally had a history of asthma. What these findings give us is a stronger rationale for setting REZPEG apart. Lately approved and in-development IL-13 selective pathway blockers along with OX40 pathway blockers have demonstrated only limited ability to assist with asthma symptoms among patients who have both atopic dermatitis and asthma — a comorbidity affecting 25% of all atopic dermatitis patients — so these fresh findings have us quite enthusiastic. During Q1, we'll share 52-week maintenance and escape arm findings from the RESOLVE-AD study in atopic dermatitis. The maintenance arm findings, especially, will offer a key look at ongoing treatment with REZPEG among patients who achieved an EASI-50 response by the close of 16 weeks of induction treatment. A need persists for novel mechanisms past what's presently available within the treatment landscape for atopic dermatitis patients. Within the U.S., more than 15 million individuals have moderate to severe atopic dermatitis, yet under 10% receive biologic treatments for this chronic skin disorder, with numerous patients responding poorly to agents that already exist. Our belief is that this market will expand through adoption of novel mechanisms, much as happened when new mechanisms were introduced during the evolution of the psoriasis market. We anticipate holding an end of Phase II meeting with the FDA prior to this year's close to go over our Phase III plans for REZPEG in moderate to severe atopic dermatitis. Significantly, in December, we intend to share top line results from the Phase IIb RESOLVE-AA study involving patients with alopecia areata. Roughly 90 patients with severe to very severe alopecia areata were enrolled in this study; given strong Phase II results within the dermatological setting of atopic dermatitis, we hold optimism regarding the second dermatological setting for REZPEG. Close to 7 million people within the U.S. have or will develop alopecia areata, and according to the 2023 population-based cohort study, over 1 million of these patients have severe to very severe disease. Those with severe to very severe alopecia face limited treatment options. JAK inhibitors are the sole FDA-approved systemic treatments for alopecia areata, and they carry multiple well-known black box warnings plus are linked to high relapse rates once discontinued; in a 2024 survey of 131 U.S.-based board-certified dermatologists, most physicians indicated discomfort with prescribing a JAK inhibitor, and over half of these physicians said they'd try alternative therapies before prescribing a JAK inhibitor; against this backdrop, REZPEG could arrive as the first biologic in the alopecia areata setting, representing an additional $1 billion market opportunity. So we eagerly await these upcoming results from the 36-week treatment period of the RESOLVE-AA study, expected in December of this year. On the immunology side, TrialNet—the partner we work with—just launched a Phase II trial of REZPEG for type 1 diabetes. TrialNet is funding and sponsoring that trial, and it's going to assess REZPEG in patients who have new onset Stage III type 1 diabetes. JZ will bring you up to speed on the rest of our programs, and also on our top pipeline antibody, which is a TNFR2 agonist with a distinctive tissue-specific Treg and Breg stimulator profile. Thanks to its monomeric activity, we are now putting together a bispecific program built around this mechanism, pairing it with validated antibody targets in immunology. Our aim is to move one of these antibody programs into the clinic next year. With that, I want to hand the call to JZ so he can walk through more details about the ongoing Phase IIb studies of REZPEG and our early pipeline programs. JZ?
Jonathan Zalevsky
executiveThanks, Howard, and I'm glad each of you could be on the call today. To start, I want to take everyone back to earlier this year, when the Phase IIb data from RESOLVE-AD made clear just how much promise Nektar's novel approach to the IL-2 pathway holds. In that global study, 393 patients with moderate to severe atopic dermatitis were randomized to receive treatment given subcutaneously. The trial tested 3 doses of REZPEG: 24 microgram per kilogram administered every 2 weeks as the high dose, 18 microgram per kilogram administered every 2 weeks as the middle dose, and 24 microgram per kilogram administered every 4 weeks as the low dose, alongside placebo given every 2 weeks, with all of this taking place over a 16-week induction period. After we reached week 16, any patient on REZPEG whose EASI score dropped by at least half was put back into randomization. They kept the same dosage but were split between a schedule of every four weeks and one of every twelve weeks, and this continued for another 36 weeks of maintenance. In June, when the data came out, we shared that the trial achieved statistical significance on its primary endpoint at week 16, measuring mean percent change from baseline in EASI score for each REZPEG group compared with placebo. Statistical significance likewise turned up for the key secondary endpoints at week 16 related to disease reduction, among them EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA. Beyond all that, no plateau has yet appeared in the response seen among the REZPEG treatment arms. That study remains underway, with 2 more data readouts coming up that Howard referenced. The initial one covers the 36-week maintenance study results, comparing REZPEG treatment at dosing intervals of either 1 month or 3 months out to a full year, representing the intended maintenance-based dosing regimens that follow the 16-week induction period. Then the other readout involves the 1-year off-treatment data, anticipated in the beginning of 2027, which will gauge the potential remittive effect of REZPEG in atopic dermatitis. Meanwhile, we keep building on the compelling data set coming out of the RESOLVE-AD study, which includes what we shared from the trial's escape arm at this year's EADV Congress. Just so everyone remembers, under how the trial was set up, those who received placebo at the start during the 16-week induction phase and whose week 16 EASI-50 response was not achieved were allowed into an open-label escape arm for treatment, and there they get the high-dose REZPEG regimen for as long as 36 weeks. Findings shared at EADV demonstrated that responses grew deeper in these patients as REZPEG treatment continued, which backs a 24-week induction period for our Phase III program. Howard noted earlier that we are also presenting more data from RESOLVE-AD on asthma patients in a late-breaking oral presentation at the ACAAI meeting, which is happening in Orlando, Florida this weekend. Aside from the asthma findings I'll discuss in a moment, that session will include a status report on the placebo crossover group, in which every participant except one has now passed the 24-week mark of therapy with REZPEG at 24 micrograms per kilogram administered every two weeks. In addition, we'll address further endpoints, including EASI-90 and itch NRS. A forest plot will likewise be presented at that time, demonstrating the degree of consistency REZPEG showed across multiple subgroups. This pivotal outcome positions us for Phase III. Because 1 in 4 atopic dermatitis patients also suffer from asthma, we planned the trial in advance to assess its impact on asthma symptoms through the validated 5-point asthma control questionnaire, or ACQ-5; and this data set contains a prespecified exploratory endpoint for the subgroup of RESOLVE-AD patients who also had asthma, including those whose asthma was moderate and uncontrolled at baseline. Being able to better manage comorbid conditions plays a major role when clinicians make treatment decisions for atopic dermatitis and might broaden the potential market opportunity for REZPEG in this setting. We are aware that aside from Dupixent, neither tralokinumab nor lebrikizumab has demonstrated an improvement in asthma symptoms among atopic dermatitis patients. This also applies to the OX40 candidates that are further along in development. Turning to alopecia areata now: things are proceeding as planned, and we anticipate sharing results from the Phase IIb trial in December 2024. Should those results be positive, they would bolster the argument that REZPEG may represent a completely novel way of treating patients with chronic skin conditions. Enrollment for the RESOLVE-AA study got underway in March 2024. In total, 94 individuals with severe to very severe alopecia areata, none of whom had prior exposure to a JAK inhibitor or any other biologic, were assigned at random to one of two REZPEG dosing schedules — 24 microgram per kilogram every 2 weeks or 18 microgram per kilogram every 2 weeks — or to placebo. Roughly thirty locations across the globe enrolled participants, and two-thirds of those individuals were based in Europe, while the rest came from North America. Keep in mind that a patient's qualification for this trial was established through the SALT score, applied both when screening and when randomizing. Anyone who, based on the investigator's judgment, experienced an unpredictable pattern of alopecia areata during the prior six months was not allowed to take part, and individuals with diffuse alopecia or additional alopecia subtypes were likewise barred. The main efficacy goal of this trial involves evaluating the mean percentage shift in the severity of alopecia tool, also known as the SALT score, once the 36-week induction phase has ended. Additional goals we're measuring include how many participants reach a SALT 20 result — meaning their absolute SALT score comes in at 20 or below — along with the average percentage change in SALT score at the other time points we evaluate, plus the share of subjects showing a reduction of at least 50% in their SALT score by week 36 and at those other assessment points. Notably, that SALT 20 responder analysis also serves as the recognized regulatory endpoint for Phase III studies. And as Howard pointed out, the sole systemic options cleared by the FDA for alopecia areata are JAK inhibitors, and those come with several black box warnings; on top of that, a large number of patients lose their hair again once they stop treatment. Given how few treatment choices exist for alopecia areata, our view is that a novel mechanism such as REZPEG has a real opening, particularly if the therapeutic proves safe and well tolerated. Looking at how RESOLVE-AA results stack up against the approved JAKs, low-dose Olumiant strikes us as the right benchmark. Across its 2 Phase III trials, the approved 2 mg dose of Olumiant demonstrated that 15% to 16% of patients reached SALT 20 on a placebo-adjusted basis at week 36, while mean improvement in SALT scores from baseline came in at 24% to 26% on a placebo-adjusted basis. One thing to note is that across those studies, the placebo response rate is quite low — between 3% and 5% on the SALT 20 endpoint, and 4% to 9% on the mean reduction endpoint. Because our mechanism of action is differentiated compared with the JAK inhibitors, and given our safety profile, we believe there's a very clear market opportunity for REZPEG in alopecia areata if REZPEG reaches these benchmarks. We're looking forward to sharing the top line data from the 36-week treatment period of the RESOLVE-AA study in December and to defining what potential REZPEG has in this new indication. Much like what we saw with atopic dermatitis, if Phase IIb delivers positive data, we'd waste little time getting Phase III ready, leveraging the Fast Track status we hold for alopecia areata. Turning briefly to type 1 diabetes — another autoimmune condition in which REZPEG could play a significant role by acting as a T regulatory mechanism. Our thinking is that REZPEG may be able to decelerate the ongoing destruction of insulin-producing beta cells, since those cells are what the patient's hyperactive immune system attacks in this disease. Howard noted earlier that TrialNet has launched a Phase II investigator-sponsored study and is paying for it, testing REZPEG in 66 individuals newly diagnosed with type 1 diabetes. Wrapping up with pipeline updates: our TNFR2 agonist, NKTR-0165, is still moving along as planned. This molecule targets TNFR2 signaling on Tregs with extremely high specificity, which boosts and fine-tunes their capacity to keep the immune system in check. Additionally, NKTR-0165 has demonstrated that a potent signal can be produced via a single-arm monovalent antibody, which makes it an ideal fit for bispecific and trispecific constructs. We aim to push one of these antibody programs into clinical testing during the next year. We're eager to provide further details about these advanced antibody engineering efforts on upcoming earnings calls. At this point, I'll hand things over to Sandy for the financial discussion. Sandy?
Sandra Gardiner
executiveThanks, JZ, and good afternoon to all of you. During this call, I'll give a quick look at our quarterly financial results and provide updates to the financial guidance we've issued for 2025. We closed out the third quarter of 2025 holding $270.2 million in cash and investments, with nothing owed on our balance sheet. As we talked about during our Q2 earnings call, the cash balance at the close of the third quarter reflects the closing of the secondary public offering in July, which brought in net proceeds of roughly $107 million. It also reflects an extra $34.3 million in net proceeds that we raised during September through our existing ATM facility. We now anticipate closing out the year with roughly $240 million in cash and investments, which is above the $100 million to $185 million we had previously guided. This raised year-end guidance also factors in $38.3 million in net proceeds from further sales under our ATM facility in October. Given our stronger year-end cash position, we are pushing our cash runway guidance out into the second quarter of 2027; and now moving on to the income statement. Our noncash royalty revenue came to $11.5 million for the third quarter of 2025. We continue to anticipate that noncash royalty revenue will reach roughly $40 million across the full year. R&D expense came in at $27.3 million for the third quarter of 2025, and we continue to expect full year R&D expense to fall somewhere between $125 million and $130 million, which includes roughly $5 million to $10 million in noncash depreciation and stock-based compensation expense. Our G&A expense came to $16.1 million for the third quarter. We continue to anticipate G&A for the full year of 2025 landing between $70 million and $75 million, including roughly $5 million to $10 million in noncash depreciation and stock-based compensation expense. Noncash interest expense for the third quarter came to $6 million, and we continue to anticipate noncash interest expense for the full year reaching roughly $20 million. Our noncash loss from equity method investment was $0.5 million in the third quarter of 2025, and we continue to expect a noncash loss of roughly $10 million for the full year 2025. As an equity investor in Gannet BioChem, we hold no obligation to put cash into Gannet. Our net loss for the third quarter was $35.5 million, or $1.87 basic and diluted net loss per share. And as I mentioned before, we now anticipate closing out the year with roughly $240 million in cash and investments, with our cash runway reaching into the second quarter of 2027. Lastly, as we approach our December data reporting, we plan to go into a quiet period for the month of December until we report the top line results for the REZPEG alopecia study. And with that, we'll now open the call for questions. Operator?
Yasmeen Rahimi
analystCongratulations on an excellent quarter. Dominic here, filling in for Yasmeen Rahimi. We have one brief question regarding the ACAAI data coming up that's going to be presented. Can you assist us in grasping what you anticipate reporting in the presentation for patients who have AD and asthma? After that, going forward, what sort of effect do you think this data would have, I suppose, on development in asthma?
Howard Robin
executiveAll right, let me — JZ is going to respond to that, though what I'd say is that right now, an asthma indication is not something we're chasing. That said, I believe it matters to acknowledge the — that with atopic dermatitis, the reality that we possess a significant drug that could potentially address that comorbidity problem is quite thrilling. And like I mentioned before, 25% of patients suffering from atopic dermatitis likewise deal with asthma as a comorbidity; therefore, it's — I consider it a really crucial element in setting REZPEG apart, even though running an asthma study isn't in our plans. JZ, could you please assist with the remainder of the question?
Jonathan Zalevsky
executiveAbsolutely. Thanks for that question, Dominic. So during the ACAAI presentation, what we're sharing are findings from a preplanned exploratory analysis that formed part of the study. There is a validated questionnaire tool — it functions as a patient-reported outcome measure — known as ACQ-5, the acronym for the asthma control questionnaire. Using it, you're able to evaluate comorbidity symptoms of asthma among patients who suffer from atopic dermatitis in addition to asthma; this then lets you examine the overall kind of change in ACQ-5 scores across time. Beyond that, it permits you to focus specifically on those whose asthma was more severe, say uncontrolled at baseline, which represents a subset of individuals scoring higher on ACQ-5 when they entered the study. For our purposes, that's genuinely compelling since, as we've talked about, about 25% of patients fall into that group, meaning around 100 subjects in our trial also suffered from asthma alongside atopic dermatitis; this gives us the ability to measure how REZPEG affects asthma control and perhaps even how much those asthma symptoms improve among patients who likewise had atopic dermatitis. Now, one point that matters enormously here is that this becomes relevant when you, as a physician, are making treatment choices. And you're aware that your patients dealing with atopy — and atopy continually involves other organ systems — which explains why such a large share of atopic dermatitis patients likewise suffer from asthma. That fact begins to shape certain treatment choices. At present, Dupi is genuinely the go-to medication for individuals with comorbidity, since Dupi has shown activity against both asthma and atopic dermatitis, in patients exhibiting both conditions as well as in each indication on its own. That's quite probably tied to the IL-4 component within its mechanism. Yet the other approved agents in this class for atopic dermatitis lack anywhere near the degree of effect that Dupi provides. So this represents a differentiating feature tied to the Treg mechanism behind REZPEG, and we believe it sets REZPEG even further apart from the remaining molecules in the class. That includes the other molecules currently in development, along with approved agents such as the IL-13 selective antagonist and the OX40 classes too. And we see this as something carrying the potential to be built upon even more with REZPEG — something we intend to explore and think about extensively going forward, both within the comorbidity setting and, as Howard mentioned, even beyond it.
Julian Harrison
analystCongratulations on everything you've accomplished lately. It seems you've had a couple of months by now to engage with physicians, discussing the early RESOLVE-AD data along with what REZPEG might offer. I'd like to know whether you've formed a clear view of how much enthusiasm exists for a treatment that may deliver a genuinely remittive benefit. How much do you believe that might become a distinguishing feature for REZPEG in atopic derm? Then moving over to alopecia areata. JZ, I caught what you said about Olumiant's low-dose efficacy magnitude possibly establishing the threshold. Do you perhaps see a chance for usage even if efficacy comes in below that, considering how safe REZPEG presumably is and that it may carry no box warnings unlike JAK inhibitors?
Howard Robin
executiveJulian, I'll handle the first portion of that question. Obviously, this mechanism — the Treg mechanism — has drawn considerable attention, particularly with the Novo Prize in physiology or medicine. And considering the very strong data we possess in atopic dermatitis along with the cross — the rescue data, or escape arm data rather, in which patients who showed no response at all on placebo did remarkably well once crossed over to drug. I believe that's extremely compelling data, and we take great pride in it. Combining that data with what we're now observing regarding the comorbidity of asthma, I believe distinguishes REZPEG from quite a few other drugs when it comes to treating atopic dermatitis. So yes, to address your question more directly, there is substantial interest in it. There's considerable inbound interest in it, and I believe its prospects are very good. I'll let JZ take the remainder of the question.
Jonathan Zalevsky
executiveAbsolutely. Thank you, Howard, and Julian. So, when we look at the benchmarks, the key thing to keep in mind is that REZPEG could become a genuinely distinct mechanism for treating alopecia areata, and that's due to several reasons. One of them relates particularly to how safe it is. At present, no biologic has received approval in the alopecia areata field. And no treatment has really shown what you'd call a lasting effect; by that I mean that even briefly pausing a JAK regimen may lead to hair thinning. It loses effectiveness very fast. So you're able to target many aspects that contribute to the disease, plus there's the ease of use for patients and, notably, the level of comfort for doctors prescribing something without a black box warning, which happens to be one of the problems and drawbacks associated with JAK inhibitors. Without a doubt, those medications work well for lowering inflammation and doing so rapidly. The issue is they're extremely hard to stay on for extended periods, and since these are long-term conditions, that's really where the difficulty lies with such a drug. However, with REZPEG, you can flip the entire situation around. And we've conducted extensive market research, we've evaluated the profile, and we've found that the profile for low-dose Olumiant is highly competitive when you consider all the other aspects and characteristics of the mechanism of action along with the distinct safety profile. And we're aware there's room there, as you mentioned, Julian. So — but for the time being, we're treating that as a sensible sort of proxy benchmark. It's a drug that's been approved at an approved dosage, yet there's still some room around it, as you pointed out.
Cheng Li
analystCheng here, filling in for Jay. Nice work on the progress. So, regarding the AA, I'd like to know how quickly you might be able to get the Phase III program underway. Also, if the December data comes back positive, do you intend to advance the program on your own or with a partner? And on a separate note, I'm curious whether any patients in the Phase IIb AD study have alopecia areata comorbidities, and if so, is there anything you can tell us about them?
Howard Robin
executiveWell, I believe I caught — I don't think I heard the first portion of your question completely. But regarding that first portion — I'll have JZ handle the second part. The first part concerned when we believe we could launch a study in alopecia areata. Depending on the data we get in December, we would definitely be eager to get it started next year. I think that matters because, as we've discussed, a JAK inhibitor is the only therapy available right now, and those carry a great many concerns and warnings. And as I mentioned, in physician surveys we've run, doctors are rather hesitant about prescribing a JAK inhibitor for alopecia areata because of safety concerns; so if we have a new modality for treating such a very serious disease and a condition that leads to extreme depression in people, I think it could be very, very important. And as a result, we do intend to begin that study next year. I'll let JZ comment on the rest.
Jonathan Zalevsky
executiveRight, thank you, Cheng. So in the atopic dermatitis Phase IIb study, we did examine several comorbidities. As I said earlier, asthma represented by far the biggest group of patients — approximately 100 individuals in that trial had both atopic dermatitis and asthma — and those findings will be presented at ACAAI this coming weekend. Regarding alopecia, we also examined vitiligo, for instance, where the numbers were extremely small; so there really weren't enough patients to carve out as a subgroup — just a small handful of individuals with alopecia who had both conditions. Clearly, our Phase IIb alopecia data, which will read out next month, is a far more definitive dataset, correct? A substantially larger sample size, and obviously a population enrolled with that as the primary disease. And then, naturally, we'll be evaluating the treatment effect in that population, reported next month.
Cha Cha Yang
analystThis is Cha Cha calling in for Roger Song. I wanted to ask, beyond low-dose Olumiant, do you see any other therapeutics currently being developed — biologics aimed at alopecia — that could serve as a suitable benchmark? Then my follow-up question: are there any studies focused specifically on IL-2 that you believe might offer read-through to REZPEG in alopecia?
Howard Robin
executiveJZ, would you like to take that one?
Jonathan Zalevsky
executiveAlright, so indeed there are a few biologic therapies being developed for alopecia, and we went over things such as an IL-7 receptor along with other types of agents, so my sense is that those — there are some earlier data sets available. What we aim to do is run a study far, far bigger than those earlier programs. As we laid out, 94 individuals were enrolled and randomized into the Phase IIb alopecia trial we are running, and we also have several dose levels. So a considerably larger trial, which provides an opportunity to genuinely evaluate the treatment effect, and I believe that will prove more informative than many of the single-arm or far, far smaller trials completed up to now; yet it is definitely a space that is being explored. Tregs stay a highly important mechanism that gets invoked across a great deal of translational research in patients who have alopecia areata; we understand there are diminished levels along with deficiencies in Treg function. We likewise understand Tregs are required for hair growth and for hair progressing through the hair growth cycle. And the specific antigen phase that is tied to the elongation of hair after it anchors down at the root in fact needs Treg signaling to the stem cell compartment. So we recognize those constitute several key mechanisms. And those are among the major reasons we are so enthusiastic about running the trial whose top line data we will be reading out next month. And regarding studies specific to IL-2, only a handful of studies involving IL-2 have been published. One was a case study, and one was a small randomized study. The key point is that low-dose IL-2 truly is not a solid proxy for REZPEG. With REZPEG, we achieve such a greater quantity of Tregs, far, far beyond what low-dose IL-2 could ever accomplish, a far longer duration of Treg elevation from any given dose, and the capacity to treat for an extremely extended period. As you are aware, we have by now treated patients for more than a year. For instance, across a 52-week period in the Phase IIb study in atopic dermatitis; so it is certainly a surrogate in the sense of being a Treg elevating agent, but in truth REZPEG considerably surpasses anything that low-dose IL-2 has managed to present across multiple indications.
Mayank Mamtani
analystCongratulations on a strong quarter. Regarding the analysis of the alopecia top line data, do you intend to report any off-treatment responder rate, considering some patients might have gone beyond that 36-week treatment window? Also, could you remind us whether an escape arm option exists here, allowing placebo non-responders to cross over? Naturally, based on your AtD experience, the peak efficacy seen in the EADV data didn't arrive until 24, 48, or even 44 weeks; so I'm curious what your plan is for evaluating whether efficacy keeps rising past that 36-week mark, and what that plan looks like? Then I have one quick follow-up.
Jonathan Zalevsky
executiveSure. Yes; so first, regarding the kind of information we'd share in December, we will present data covering the study's 36-week induction period. The primary endpoint is the mean percent reduction in SALT score from baseline; and the key secondary endpoints that are truly, truly meaningful are the proportion of people achieving SALT 20 as well as SALT 10. SALT 20 serves as the registrational endpoint in the U.S., while SALT 10 is for Europe. And as I noted earlier in the presentation, there are also additional secondary endpoints, some time-dependent endpoints, and some proportional increases in hair regrowth, right, as metrics. And the other thing that helps round out the baseline demographics, the safety profile, all the other items. But importantly, Mayank, right, the study will still be ongoing; so as you know, the way we designed the study is that people who reached week 36 and are experiencing benefits such as hair regrowth, for example, but who have not yet reached a SALT 20 metric, they get the chance to take an additional 16 weeks of treatment, reaching 52 weeks for a full year. So a proportion of people will be ongoing. And the study design also includes a 24-week off-drug observation period. So whenever a patient finishes treatment, whether that happens at 9 months or 12 months, they are then followed for that additional 24-week period of time. And that's really designed to assess whether, if you grew hair, you can keep hair, right, which is a significant differentiating element from a JAK mechanism of action, where hair loss becomes really, really rapid once drug dosing stops; so because the study is still ongoing, I mean, we can't yet state the totality. But definitely, the 36-week endpoint, which is the primary analysis with the entire population crossing the 36-week mark, is going to be the main subject of that top line presentation.
Mayank Mamtani
analystIs there an escape arm in this arm—an escape arm, I mean?
Jonathan Zalevsky
executiveIn the study, no escape arm exists.
Mayank Mamtani
analystAll right. Regarding the auto-injector program, what stage is that at? Will it be ready when your Phase III trial begins? And as you move toward the end-of-Phase II conversation, is that essentially included in the protocol?
Jonathan Zalevsky
executiveCertainly. Yes. Work on the auto-injector continues. Our aim and strategy is for the auto-injector to be ready when REZPEG launches. The Phase III trials will follow the same approach as the Phase II trials, with the drug administered from a vial. For us — we keep it that way mainly for speed, since doing so lets us kick off the Phase III trials as soon as possible after we shared the top line data in June of this year. Then, addressing your second question, in the setting of an end of Phase II meeting, essentially everything in the plan leading to your BLA gets discussed. That covers not only the Phase III clinical development program — the registrational and pivotal studies — but the CMC as well. So yes, we have laid out our plans for the final presentation of the product, the auto-injector, and then all the work we do during the Phase III trials into the BLA so that it's ready for launch.
Arthur He
analystI'm sorry, and my apologies if this has come up already. With the readout we're expecting for alopecia, JZ, could you maybe share more about what REZPEG might potentially bring to alopecia patients versus a JAK inhibitor?
Jonathan Zalevsky
executiveSure, that's a wonderful question. I think one thing about JAK inhibitors — and we went into this a bit before — is that they clearly work well for bringing down inflammation. For instance, when common gamma chain is involved across multiple cytokines, engaging either homo or heterodimers of JAKs, that's a key piece of the signaling cascade triggered by multiple cytokines, and these drugs are recognized for reducing inflammation fairly rapidly. However, the problem with any approved indication for a JAK inhibitor is that using them over the long haul comes with certain drawbacks, correct? These drugs carry black box warnings. They come with other meaningful limitations. Monitoring is required. There are simply various factors that make them somewhat trickier to handle. And in dermatology, a few of those factors are somewhat less than ideal. So what REZPEG may be able to provide is this: if the efficacy, as we talked about, hits a benchmark like a low-dose JAK — in the Olumiant setting, let's say — it arrives with an entirely different risk profile, correct? No black box warning would apply, the safety profile would be entirely different and far, far superior, and that profile would line up much better with a drug intended for very long-term chronic use. Beyond that, the possibility of becoming the first biologic in this area hands us a truly enormous edge, since that begins to genuinely unlock access, because we've seen across many studies that physicians aren't necessarily all that eager to reach for JAKs as the initial choice for patients who have this disease. So an additional option being on the table could deliver a considerable — an opportunity advantage. And the final point really boils down to that maintenance potential. JAK inhibitors actually stop working very fast; and this can be psychologically very hard on patients, because when you've spent weeks and months regrowing hair you hadn't had for a really long time and then any need arises to stop the JAK — a safety signal, some other reason, liver enzyme elevation, anything like that — that can cause you to lose every bit of the hair you grew, which can push the depression cycle even further. That's one aspect of this disease. With REZPEG, there's a chance of keeping the hair that grew, with interruptions in dosing no longer posing a problem. And that would be utterly transformational; so all of these, we believe, add up to a very substantial opportunity for REZPEG and alopecia areata.
Arthur He
analystThen, turning to the next item, since you've already included that information in the data, what should our expectations be regarding the main endpoint for the upcoming approval? Is it your view that SALT 20 can still get the job done? Or is it more likely that we ought to be considering SALT 10, or perhaps even SALT 0, for the alopecia drug going forward?
Jonathan Zalevsky
executiveYeah. Well, I'd say the regulatory agency determines what the registrational endpoints are, correct? So at this point, those have been established, correct, as SALT 20 within the U.S. alongside SALT 10 across Europe. Yet clearly, each trial captures a number of secondary measures, correct, such as eyelash, such as SALT 0, and others too. So my view is that this is something we hand over to the regulators. When it comes to how well UPA works, I'd say — it seems that in every place where several JAK inhibitors have gotten approval, UPA or RINVOQ tends to come out on top, correct? It reliably delivers the highest level of efficacy whenever it's tested directly against competing agents. And I believe we've observed this across several indications, Arthur, correct, not only in dose 1; it does bring along a somewhat larger safety burden, which is tied to the mechanism, correct? It's more on target, and more on-target tox besides other factors; however, I do believe that relative to the remaining JAK inhibitors, UPA will prove quite important, likely securing a meaningful position versus the other JAK inhibitors. That said, we don't truly view this as having an effect on the biologics, correct? Once more, there are many indications in which biologics and small molecules, JAKs and non-JAKs, exist side by side. Atopic dermatitis is an excellent illustration. In psoriasis, you've got the TYK2 mechanism existing alongside others. And there truly is a sufficiently large patient share and a demand for multiple mechanisms that there's consistently ample space for multiple mechanisms in this indication.
Tsan-Yu Hsieh
analystMary, welcome back — really good to see you. Two things from us. First, regarding RESOLVE-AD, my sense is that a great deal of time and resources went into keeping the placebo rate down, so have you had the opportunity to go over that effort, so that we're in the strongest possible position for a positive Phase III result? Second, this may be one for Howard: what does your manufacturing footprint look like right now? Given how much interest there is in REZPEG, it would be terrific if you could lock in one of those national priority vouchers.
Howard Robin
executiveLet me handle the second one first, then Mary can pick up. We're evaluating several different possibilities on that front. Our PEGylation manufacturing facility was sold to Gannet BioChem, though we hold a priority position there, and we definitely have an assured supply of those raw materials. On top of that, we have multiple contract manufacturing partners — very well-known companies — that we work with. So at this point I have no worry about our ability to manufacture REZPEG successfully, and we are exploring the vouchers and so forth. I'll let Mary address the remaining portion of your question.
Mary Tagliaferri
executiveHoward, thank you. Andy, it's genuinely wonderful to hear your voice as well, and I'm delighted to be back. As you mentioned, the RESOLVE-AD data are truly thrilling. Since returning, I've spoken with a number of dermatologists, and they're equally enthusiastic about the full picture of the results — how quickly it takes effect and its outstanding safety profile. So pushing this ahead is very exciting. In our Phase III program, we absolutely intend to carry out the very same steps we used to keep the placebo effect as small as possible. Among those steps, naturally, is making certain that board-certified dermatologists take part in our trials. We also confirm that eligibility criteria are satisfied at screening and again just before randomization of patients. So we've taken a number of measures. Additionally, in our Phase IIb, our placebo group was fairly large, and we will, naturally, do the same as we move ahead into a bigger Phase III study. We were therefore quite pleased to have put in place a range of different steps and activities to keep our placebo effect extremely low, and we're confident we'll keep enjoying strong success in Phase III too. So we're eager to move ahead. We've done considerable planning. Our end of Phase II meeting with the FDA will take place by the close of this year, and then we'll have a clear route toward a BLA.
Howard Robin
executiveOkay, thanks Crystal, and thanks to all of you for being with us today — we truly appreciate your ongoing support. I'd also like to express my gratitude to every patient and caregiver who has placed and continues to place their trust in Nektar for treating their condition. Without them, none of this research could happen. My thanks go out as well to our team members for their commitment and their truly tireless efforts, and we're eager to share data from our REZPEG program in alopecia areata in December, along with further findings from that program in atopic dermatitis during the first quarter of next year. So keep an eye out. Thank you for being here.
Operator
operatorThat brings us to the end of today's conference call. We appreciate everyone taking part. You're welcome to disconnect at this point. Have a great day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.